Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG IR NMIBC) requires recurrent bladder tumor transurethral resections performed under general anesthesia. The gold standard of therapy for treating LG IR NMIBC is transurethral resection of bladder tumor (TURBT), which is frequently performed while the patient is under general anesthesia. Each year, approximately 275,000 people are diagnosed with bladder cancer worldwide, and 108,000 people pass away from the condition. 90% of bladder cancers in developed nations are TCC. The majority of bladder cancers in developing nations, particularly in the Middle East and Africa, are squamous cell carcinomas, and most of these cancers are brought on by schistosome infection. Low grade, noninvasive, papillary tumors make up nearly half of all newly diagnosed bladder cancer cases. Transurethral resection of the bladder tumor (TUR-BT), with or without adjuvant intravenous chemotherapy or Bacillus Calmette-Guerin (BCG) therapy, has been the accepted treatment for non-muscle-invasive bladder cancer (NMIBC).

Description

Low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG IR NMIBC) requires recurrent bladder tumor transurethral resections performed under general anesthesia. The gold standard of therapy for treating LG IR NMIBC is transurethral resection of bladder tumor (TURBT), which is frequently performed while the patient is under general anesthesia. It is recommended by U.S. to administer adjuvant intrathecal chemotherapy, national recommendations, but peer-reviewed literature shows that this is not frequently done in clinical practice for a number of reasons, including concern about long-term bladder damage, inconvenience, and a lack of confirmation of malignancy. Adjuvant intravesical immunotherapy is also suggested, though for patients with IR NMIBC, this course of therapy has been hampered by the widespread scarcity of bacillus Calmette-Guerin. Repeated TURBTs under general anesthesia are the most common form of treatment for people with LG IR NMIBC because of the risks involved.

Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) (Epidemiology)

Each year, approximately 275,000 people are diagnosed with bladder cancer worldwide, and 108,000 people pass away from the condition. 90% of bladder cancers in developed nations are TCC. The majority of bladder cancers in developing nations, particularly in the Middle East and Africa, are squamous cell carcinomas, and most of these cancers are brought on by schistosome infection. The most prevalent type of urinary tract cancer in China is thought to be urothelial carcinoma. In endemic schistosomiasis regions of Africa, particularly in Sudan and Egypt, where CSC accounts for two-thirds to three-quarters of all bladder malignancies, SCC is most prevalent. Recent studies from Egypt have indicated that, despite the fact that the situation has remained unchanged in other regions of Africa, this trend has reversed as a result of improved schistosomiasis control in the region. It is believed that rising smoking rates helped Egypt make the switch to TCC, which has a stronger association with smoking.

Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) -Current Market Size & Forecast Trends

The market for low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR-NMIBC) is expected to experience significant growth, driven by the increasing incidence of non-muscle invasive bladder cancer and the development of new treatment options. The overall non-muscle invasive bladder cancer market is projected to grow from approximately USD 2.5 billion in 2023 to around USD 3.6 billion by 2030, reflecting a compound annual growth rate (CAGR) of about 5.4% during this period.

For LG IR-NMIBC specifically, ongoing clinical trials, such as those involving UGN-102, are showing promising results and could potentially reshape treatment paradigms if successful. The increasing focus on personalized medicine and improved diagnostic techniques are also expected to contribute to market expansion. North America is anticipated to dominate the market due to its advanced healthcare infrastructure and high prevalence of bladder cancer.

Overall, the LG IR-NMIBC market is well-positioned for substantial growth through 2035, supported by innovative therapies and a growing emphasis on early diagnosis and effective management strategies.

Low grade, noninvasive, papillary tumors make up nearly half of all newly diagnosed bladder cancer cases. Transurethral resection of the bladder tumor (TUR-BT), with or without adjuvant intravenous chemotherapy or Bacillus Calmette-Guerin (BCG) therapy, has been the accepted treatment for non-muscle-invasive bladder cancer (NMIBC). Guidelines for defining IR NMIBC differ from one another. The IBCG advises defining IR NMIBC as any TaLG tumor that is either recurrent or multifocal or has size 3 cm, OR any T1LG tumor. Any TaG2 tumor, regardless of whether it is a new diagnosis or a recurrence, would be regarded as an IR disease under the three-tier grading system. It's important to grade and stage tumors accurately, especially when trying to rule out HG/G3 disease and/or carcinoma in situ. The management of IR NMIBC should, according to the IBCG, be further based on the risk factors of multifocal tumor (more than one), early recurrence (1/yr), tumor size (3 cm), and failure of prior intravesical treatment. The best course of treatment for patients without risk factors is one dose of postoperative intrathecal chemotherapy. Patients with one to two risk factors ought to be given extra adjuvant induction intravesical chemotherapy (or BCG if prior chemotherapy has been given) or both. Patients should be given an induction plus a one-year maintenance BCG course if they have three or more risk factors. Alternative intravesical treatments like chemotherapy (single agent, combination, or chemo hyperthermia) or a clinical trial are advised in cases where BCG is not available or recurrent disease after BCG is present.

Report Highlights

Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) - Current Market Trends

Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) - Current & Forecasted Cases across the G8 Countries

Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) - Market Opportunities and Sales Potential for Agents

Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) - Patient-based Market Forecast to 2035

Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) - Untapped Business Opportunities

Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) - Product Positioning Vis-a-vis Competitors' Products

Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) - KOLs Insight